Market Overview

Innovus Pharma to Launch of EjectDelay for Premature Ejaculation


Innovus Pharmaceuticals (OTC: INNV) today announced that the Company will initiate a nationwide sampling of its topical benzocaine-based premature ejaculation FDA OTC compliant product EjectDelay through the American Urology Association's ("AUA") sampling program. Pursuant to the sampling program, each of the approximately 9,000 urologists in the U.S. will be receiving two samples of the product. The Company anticipates the sampling program to be completed within six to eight weeks.

"We believe that a nationwide sampling program is an important tool for a successful launch as it allows physicians to experience firsthand patient responses to a product. We are excited about the progress we are making towards our projected launch of EjectDelay in the U.S. for the fourth quarter of this year," said Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. "Our contract sales representatives and our co-promotion partner, Consortia Health, are ready to make this product available in the US as soon as the sampling program is completed," said Robert C. Verfurth, Vice President of Sales and Marketing of the Company.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (INNV)

View Comments and Join the Discussion!

Ocwen Financial Amends Credit Facility, Repurchases Shares From WL Ross

AngioDynamics Announces Debt Refinancing